Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Clinical and Translational Science
|
May 15, 2020
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
Yaowei Zhu, Yan Xu, Yanli Zhuang, et al.
Clinical Pharmacokinetics
|
March 3, 2007
Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin
Richa Chandra, Ping Liu, Jeanne D Breen, et al.
The Oncologist
|
August 4, 2007
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
Antoni Ribas, Douglas C Hanson, Dennis A Noe, et al.
Journal of Clinical Pharmacology
|
February 19, 2019
Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects
Derrick E Akpalu, Bart Frederick, Ivo P Nnane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2008
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
Martha Q Lacy, Melissa Alsina, Rafael Fonseca, et al.
Journal of Clinical Pharmacology
|
February 11, 2005
CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations
Rujia Xie, Lai Hock Tan, Emery C Polasek, et al.
Therapeutic Advances in Cardiovascular Disease
|
August 1, 2019
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome
Liping Zhang, Xiaoyu Yan, Partha Nandy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2005
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
Antoni Ribas, Luis H Camacho, Gabriel Lopez-Berestein, et al.
Journal of Clinical Pharmacology
|
October 28, 2021
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis
Man Melody Luo, Peijuan Penny Zhu, Ivo Nnane, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Clinical and Translational Science
|
May 15, 2020
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
Yaowei Zhu, Yan Xu, Yanli Zhuang, et al.
Clinical Pharmacokinetics
|
March 3, 2007
Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin
Richa Chandra, Ping Liu, Jeanne D Breen, et al.
The Oncologist
|
August 4, 2007
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
Antoni Ribas, Douglas C Hanson, Dennis A Noe, et al.
Journal of Clinical Pharmacology
|
February 19, 2019
Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects
Derrick E Akpalu, Bart Frederick, Ivo P Nnane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2008
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
Martha Q Lacy, Melissa Alsina, Rafael Fonseca, et al.
Journal of Clinical Pharmacology
|
February 11, 2005
CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations
Rujia Xie, Lai Hock Tan, Emery C Polasek, et al.
Therapeutic Advances in Cardiovascular Disease
|
August 1, 2019
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome
Liping Zhang, Xiaoyu Yan, Partha Nandy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2005
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
Antoni Ribas, Luis H Camacho, Gabriel Lopez-Berestein, et al.
Journal of Clinical Pharmacology
|
October 28, 2021
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis
Man Melody Luo, Peijuan Penny Zhu, Ivo Nnane, et al.
Page
of 5